Furthermore, drugs targeting the mRNA translation machinery, including eFT508 (MNK1/2 inhibitor) and silvestrol (eIF4A inhibitor), reduce PD-L1 expression by tumor cells in models of liver cancer and melanoma, sensitizing tumors to T cell-dependent immune responses [133,134]. This evidence concerns the gene CD274 and melanoma.